When did informed consent become, You are informed that you consent?

[Guest guest]

I came across this interesting post on the UK JABS Forum:

http://www.jabs.org.uk/forum/topic.asp?TOPIC_ID=4323

From: Binstock When did "informed consent" become, You are informed that you consent?Lancet editorial re: swine flu vax caution attached herewithly. The editorial advises caution but avoids expressing concern for effects of vaccine components such as thimerosal, aluminum, squalene (1), etc.I am saddened that I've come to accept that the primary purpose of the H1N1 pandemic and the H1N1 mass-vaccination crusade is to induce chronic pathologies (eg, 1) which shall generate billions in ongoing revenues.1. Squalene: The Swine Flu Vaccine’s Dirty Little Secret ExposedBy Dr. Mercolahttp://articles.mercola.com/sites/articles/archive/2009/08/04/Squalene-The-Swine-Flu-Vaccines-Dirty-Little-Secret-Exposed.aspxwww.thelancet.com Vol 374 August 1, 2009EditorialLast week, Australia and the USA announced that theywould begin trials of an H1N1 vaccine. Vaccination againstH1N1 will be an important development in controllingthe impact of the pandemic. However, several thornyissues exist around vaccine manufacture and approval.All countries will require the vaccine but current globalmanufacturing capacity will not be able to meet thisdemand. Additionally, experts think that individuals mightneed two doses of the vaccine instead of one, reducingcapacity further. Vaccine manufacturers are also strugglingto produce good vaccine yields with the H1N1

seed virus.One way to ease these supply problems is the useof adjuvants in a vaccine. On July 7, WHO’s StrategicAdvisory Group of Experts on Immunizationrecommended that vaccine formulated with oil-inwateradjuvants and live-attenuated influenza vaccinesshould be promoted to help increase the global supplyof a vaccine and because they are better at protectingagainst strain variations. Yet there are signs that the USAmight not follow this recommendation. “Adjuvant usewould be contingent upon showing that it was neededor clearly beneficialâ€, Goodman, acting chiefscientist and deputy commissioner of the Food and DrugAdministration told a press briefing on July 17. The USAmust support the use of dose-sparing strategies to avoiddepletion of an already short vaccine supply.As well as availability, safety of an H1N1 vaccine is aconcern. Many national regulatory agencies have

setupfast-track approval processes for the H1N1 vaccine,which means that a vaccine might be licensed withoutthe usual safety and efficacy data requirements. Vaccinesafety will therefore have to be monitored through postmarketingsurveillance.But some fear a repeat of the1976 H1N1 outbreak in the USA, where mass vaccinationwas associated with complications, which stopped thecampaign and led to the withdrawal of the vaccine.Countries need to assess carefully the risks andbenefits of rapid approval of an H1N1 vaccine, especiallysince the disease has so far been mild with most patientsmaking a full recovery. They must also ensure that theyhave strong post-marketing surveillance in place beforerolling out a vaccine. #65533;¡ The Lancet<http://d.yimg.com/kq/groups/1957724/11780560/name/Lancet%202009%20HIN1%20vaccination%20editorial%20-%20August%2Epdf>Lancet 2009 HIN1 vaccination editorial -<http://d.yimg.com/kq/groups/1957724/11780560/name/Lancet%202009%20HIN1%20vaccination%20editorial%20-%20August%2Epdf>August.pdf